comparemela.com
Home
Live Updates
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS : comparemela.com
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...
Related Keywords
Canada
,
Ireland
,
United Kingdom
,
Cambridge
,
Cambridgeshire
,
Germany
,
Belgium
,
Netherlands
,
Italy
,
Massachusetts
,
United States
,
Seanm Healey
,
Angela Genge
,
Kevin Eggan
,
Department Of Neurosciences
,
Prnewswire Quralis Corporation
,
Hospital Centre
,
Hospital Research Centre
,
University Of Montr
,
Eggan Lab
,
Alis Corporation
,
Merit Cudkowicz
,
Massachusetts General Hospital
,
Julieanne Dorn Professor
,
Harvard Medical School
,
Qurali Clinical Advisory
,
Quralis
,
comparemela.com © 2020. All Rights Reserved.